SpeeDx Awarded REDI Fellowship to Support the development of Next Generation detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*

In collaboration with researchers at The University of Technology Sydney, focusing on developing & commercialising a product that has the potential to transform STI patient management

SYDNEY, AUSTRALIA — (November 15, 2022). SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, announced it has been awarded a Researcher Exchange and Development within Industry (REDI) Fellowship. "Associate Professor Nham Tran is a Program Leader and Research Fellow from the University of Technology Sydney will undertake a 12-month project with SpeeDx Pty Ltd.

A/Prof Tran's research will focus on bringing a new assay, (***In****Signia*®), which is currently in its early stage of development, for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*, into the product development lifecycle for future commercialisation. ***In****Signia*® has the potential to transform STI patient management and will help in the efforts to minimise the overuse of antibiotics."

The $32 million REDI Fellowship Program is supported by MTPConnect's Researcher Exchange and Development within Industry (REDI) initiative funded by the Medical Research Future Fund (MRFF). REDI provides industry experience and skills development for researchers, clinicians and other professionals within MTP (medical technology, biotechnology and pharmaceutical) industry and aims to build the skills and capacity to build the rapidly changing MTP sector.

Neisseria gonorrhoeae is a sexually transmitted bacterial infection, which infects the mucous membranes of the reproductive tract, including the cervix, uterus, and fallopian tubes in women, and the urethra in women and men. And, if left untreated, may cause infertility.
This Sexually Transmitted Infection (STI) 'superbug' is fast becoming resistant to many antibiotic treatments, leading to exceedingly difficult-to-treat infections, and threatening global public health.

We are able to continue this valuable work through the ongoing support of The ARC ITRP Research Hub to Combat Antimicrobial Resistance in collaboration between the following organisations: Australian universities: UNSW Sydney (Kirby Institute, Centre for Social Research in Health), University of Queensland, Monash University, UTS and University of Melbourne.

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com

Contacts
SpeeDx
Michelle Howie – Global Strategic Marketing Manager
+61 499 743 199